News & Events
January 29, 2008
Surface Logix Achieves Objectives with SLx-4090 in Phase 2a Clinical Trial
January 8, 2008
Surface Logix Achieves Objectives with SLx-2101 in Phase 2a Clinical Trial in Hypertension
November 26, 2007
Surface Logix, Inc. to present at the Piper
Jaffray Health Care Conference
October 18, 2007
Surface Logix SLX-4090 Selected Among Top 10 Most Promising Licensing Candidates in Cardiovascular Disease
October 5, 2007
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLX-4090 at the 16th International Symposium on Drugs Affecting Lipid Metabolism
October 3, 2007
Surface Logix Inc. To Present at the 2007 Bio Investor Forum
August 21, 2007
Surface Logix Announces the Appointment of Leland Webster as Vice President of Corporate Development
June 28, 2007
Surface Logix Commences Phase 2a Clinical Trial of Slx-2101 in Raynaud’s Disease
June 19, 2007
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Hypertension
June 7, 2007
Surface Logix Starts Phase 2a Clinical Trial of SLx-4090 in Dyslipidemia
April 7, 2007
Surface Logix Inc. Raises $20 Million in Second Tranche of Series D Financing
March 26, 2007
Surface Logix, Inc. to Present at the Future Leaders in the Biotech Industry Conference
February 8, 2007
Surface Logix Inc. To Present at BIO CEO & Investor Conference 2007
|
2006
|
|
December 11, 2006
Surface Logix Inc. To Present At The RBC Capital Markets Healthcare Conference
November 27, 2006
Surface Logix Inc. to Present at the Piper Jaffray Healthcare Conference
November 14, 2006
Surface Logix Presents Positive Phase 1 Trial Data on SLX-4090 at American Heart Association (AHA) Annual Meeting
November 2, 2006
Surface Logix SLx-2101 Selected as One of 10 Most Promising Cardiovascular Drugs in Development
October 17, 2006
Surface Logix, Inc. to present at the 2006 Bio Investor Forum
September 6, 2006
Surface Logix Appoints W. James O’Shea to Board of Directors
June 28, 2006
Surface Logix Announces the Appointment of Bridget McCarthy, Ph.D., as Vice President of Chemistry
June 13, 2006
Surface Logix Inc. to Present at The Pacific Growth Equities 2006 Life Sciences Growth Conference.
May 23, 2006
Surface Logix Reports Data On Slx-2101 For Erectile Dysfunction At The American Urological Association Meeting.
May 22, 2006
Surface Logix Inc. Named a Red Herring 100 Winner.
March 14, 2006
Surface Logix Commences Phase 1 Trial for Novel Gastrointestinal-Specific MTP Inhibitor.
January 25, 2006
Surface Logix appoints Steven Gillis, Ph.D. to Board of Directors.
|
|
|
Archive
|
|
November 30, 2005
Surface Logix Commences Phase 1Ia Trial for Novel PDE5 Inhibitor SLX-2101 in Patients with Endothelial Dysfunction.
November 18, 2005
Surface Logix reports data on SLX-2101 for erectile dysfunction and endothelial dysfunction at the Sexual Medicine Society of North America meeting.
November 1, 2005
Surface Logix to Present Clinical Candiate for Dyslipdemia and Obesity at The American College of Gastroenterology Scientific Meeting
October 28, 2005
Surface Logix Inc. Announces $42 Million Private Financing to Advance Clinical Programs
October 11, 2005
Surface Logix Phase 1 Clinical Trial Achieves Target Profile
October 10, 2005
Surface Logix announces the appointment of John Wm. Ferkany, Ph.D., M.A.S. as Vice President of Biology
September 23 , 2005
Surface Logix appoints Schering Executive, Marc Rubin, M.D., to Board of Directors
June 8, 2005
Surface Logix Commences Phase 1 Trial for Novel PDE-5 Inhibitor
February 17, 2005
Surface Logix announces the appointment of Dr. Warwick Tong as Senior Vice President, Commercial Development
|
|
